Purushoth Ethiraj

Dr. Purushoth Ethiraj

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2024 in Science Advances
Verified
Journal Article
Open access
ZQZhijun Qiu
Zhijun Qiu
JKJihane Khalife
Jihane Khalife
PEPurushoth Ethiraj
Purushoth Ethiraj
CJCarine Jaafar
Carine Jaafar
ALAn-Ping Lin
An-Ping Lin
RARicardo C. T. Aguiar
Ricardo C. T. Aguiar
The mechanism by which interferon regulatory factor 8 (IRF8) mutation contributes to lymphomagenesis is unknown. We modeled IRF8 variants in B cell lymphomas and found that they affected the expression of regulators of antigen presentation. Expression of IRF8 mutants in murine B cell lymphomas suppressed CD4, but not CD8, activation elicited by antigen presentation and downmodulated CD74 and human leukocyte antigen (HLA) DM, intracellular regulators of antigen peptide processing/loading in the major histocompatibility complex (MHC) II. Concordantly, mutant IRF8 bound less efficiently to the promoters of these genes. Mice harboring IRF8 mutant lymphomas displayed higher tumor burden and remodeling of the tumor microenvironment, typified by depletion of CD4, CD8, and natural killer cells, increase in regulatory T cells and T follicular helper cells. Deconvolution of bulk RNA sequencing data from IRF8-mutant human diffuse large B cell lymphoma (DLBCL) recapitulated part of the immune remodeling detected in mice. We concluded that IRF8 mutations contribute to DLBCL biology by facilitating immune escape.

8 January 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
ALAn-Ping Lin
An-Ping Lin
ZQZhijun Qiu
Zhijun Qiu
PEPurushoth Ethiraj
Purushoth Ethiraj
BSBinu Sasi
Binu Sasi
CJCarine Jaafar
Carine Jaafar
RARicardo C. T. Aguiar
Ricardo C. T. Aguiar

1 August 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
PEPurushoth Ethiraj
Purushoth Ethiraj
KVKarpagam Veerappan
Karpagam Veerappan
SSShila Samuel
Shila Samuel
SSSundaresan Sivapatham
Sundaresan Sivapatham

6 July 2021 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
PEPurushoth Ethiraj
Purushoth Ethiraj
IHIshraq A. Haque
Ishraq A. Haque
AAAnna K. Alford
Anna K. Alford
WGWenyu Gou
Wenyu Gou
TSToolika Singh
Toolika Singh
SRSakamuri V. Reddy
Sakamuri V. Reddy

18 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ADAdolfo Enrique Diaz Duque
Adolfo Enrique Diaz Duque
PFPedro S. S. M. Ferrari
Pedro S. S. M. Ferrari
PEPurushoth Ethiraj
Purushoth Ethiraj
Carine JaafarCarine Jaafar
Carine Jaafar
ZQZhijun Qiu
Zhijun Qiu
RARicardo C. T. Aguiar
Ricardo C. T. Aguiar
Background: Diffuse large B-cell lymphoma (DLBCL) is a common and often fatal malignancy. The standard-of-care immunochemotherapy, R-CHOP, cures only about 60% of DLBCL patients. Improving this cure rate will likely require the effective translation of basic biology knowledge into clinical activities. We previously identified the cyclic-AMP/phosphodiesterase 4 (PDE4) axis as an important modulator of lymphomagenic processes. We also showed that the FDA-approved PDE4 inhibitor roflumilast can suppress B-cell receptor (BCR) signals, phosphoinositide 3-kinase (PI3K) activity and angiogenesis. These data suggested that combining roflumilast with R-CHOP may be beneficial in DLBCL. Methods: We conducted a single-center, single-arm, open-label, phase 1 study of roflumilast in combination with the standard of care, R-CHOP (Ro+R-CHOP), in pathologically proven, treatment-naïve, high-risk DLBCL patients. Results: Ro+R-CHOP was safe, and at a median follow-up time of 44 months, 70% of patients were alive and disease free (median OS not reached, PFS 44% (95% CI, 21–92). In this pilot series, we found that the addition of roflumilast suppressed PI3K activity in peripheral blood mononuclear cells, and VEGF-A secretion in the urine. We also encountered preliminary evidence to suggest that the Ro+R-CHOP combination may be particularly beneficial to patients diagnosed with high-risk genetic subtypes of DLBCL, namely MCD and A53. Conclusions: These initial findings suggest that roflumilast may be an alternative agent able to inhibit BCR/PI3K activity and angiogenesis in DLBCL, and that the testing of Ro+R-CHOP in a larger series of genetically characterized tumors is warranted. This study was registered at ClinicalTrials.gov, number NCT03458546.